Acute Leukaemia



Dr Durga Moratuwagama

- Definition
- Classification
- Clinical features
- Diagnosis
- Treatment



Acute leukaemia

- Malignant transformation at HSC/Early progenitors

1. Block in cellular differentiation
2. Increased proliferation
3. Reduced apoptosis

Accumulation of early haemopoietic cells ‘Blasts’

Two-hit model of leukemogenesis

Loss of function of transcription factors needed for differentiation

eg. AML1-ETO
CBFβ-SMMHC
PML-RARα

Gain of function mutations of tyrosine kinases

eg. FLT3, c-KIT mutations
N- and K-RAS mutations
BCR-ABL
TEL-PDGFβR




ALL
naïve
germinal center
B-lymphocytes
Plasma cells
Lymphoid progenitor
T-lymphocytes
Hematopoietic stem cell
AML
Myeloid progenitor
Neutrophils
Eosinophils
Basophils
Monocytes
Platelets
Red cells

Myeloid maturation



Adapted and modified from U Va website

How many blast cells?

- Peripheral Blood-No blasts
- Normal BM < 5%
- **Blasts > 20% in blood or BM**



Normal human blood



Blood with leukemia



Normal bone marrow



Bone marrow with acute leukaemia

Classification of Leukaemia

Lineage	Acute	Chronic
Myeloid	Myeloblastic (AML)	Myeloid(CML)
Lymphoid	Lymphoblastic (ALL)	Lymphocytic(CLL)

Leukaemia

- Acute leukaemias: rapid onset, rapid death if treatment is not successful
- Chronic leukaemias: natural history measured in years, even without initial treatment

Classification of acute leukaemias

ALL

- mainly children

Commonest childhood cancer

- **curable in 85% of children**
- curable in minority of adults

AML

- mainly adults

- curable in minority of adults

Classification of AML & ALL

TABLE 1: 2008 WHO classification of acute myelogenous leukemia (AML)

AML with recurrent genetic abnormalities
AML with t(8;21)(q22;q22); *RUNX1-RUNX1T1*
AML with inv(16)(p13,1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11*
AML with t(15;17)(q22;q12); *PML-RARA*
AML with t(9;11)(p22;q23); *MLLT3-MLL*
AML with t(6;9)(p23;q34); *DEK-NUP214*
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); *RPN1-EVI1*
AML (megakaryoblastic) with t(1;22)(p13;q13); *RBM15-MKL1*
Provisional entity: AML with mutated *NPM1*
Provisional entity: AML with mutated *CEBPA*
AML with myelodysplasia-related changes
Therapy-related myeloid neoplasms
AML, not otherwise specified
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia
Acute erythroid leukemias
Pure erythroid leukemia
Erythroleukemia, erythroid/myeloid
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma

WHO = World Health Organization

Swerdlow SH, Campo E, Harris NL, et al (eds): WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 109–138, 2009.

Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937–951, 2009

Acute lymphoblastic leukemia (ALL):

WHO classification

Precursor lymphoid neoplasms
B-cell lymphoblastic leukemia/lymphoma, not otherwise specified
B-cell lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
B-cell lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); *BCR-ABL1*
B-cell lymphoblastic leukemia/lymphoma with t(v;11q23); *MLL* rearranged
B-cell lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); *TEL-AML1 (ETV6-RUNX1)*
B-cell lymphoblastic leukemia/lymphoma with hyperploidy
B-cell lymphoblastic leukemia/lymphoma with hypoploidy (hypodiploid ALL)
B-cell lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); *IL3-IGH*
B-cell lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); *E2A-PBX1 (TCF3-PBX1)*
T-cell lymphoblastic leukemia/lymphoma

WHO = World Health Organization

Swerdlow SH, Campo E, Harris NL, et al (eds): WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 109–138, 2009.

http://imaging.ubmmedica.com/cancernetwork/cmhb13/13_29_Table2.gif

Risk Factors-AML

- Pre-existing haematological disorders
- Age - Older adults are more likely to develop AML
- Smoking
  - **20% of AML cases are linked to smoking**
  - **Doubles** the risk of disease in people older than 60
- Genetic disorders - Down syndrome, Fanconi anemia
- High doses of radiation
  - **Long-term survivors of atomic bombs**
- Previous chemotherapy treatment
  - **Breast cancer, ovarian cancer, lymphoma**
- Exposure to industrial chemicals - Benzene

Risk Factors-ALL

- Prenatal exposure to x-rays
- Postnatal exposure to high doses of radiation (e.g., therapeutic radiation as previously used for conditions such as tinea capitis and thymus enlargement)
- Exposure to high levels of certain chemicals, such as benzene, which is used in oil refineries, chemical plants, and other industries
- Genetic conditions, including Down syndrome, neurofibromatosis, Shwachman-Diamond syndrome, Bloom syndrome, ataxia-telangiectasia, Diamond-Blackfan anemia, Fanconi anemia, Klinefelter syndrome, Li-Fraumeni syndrome, and trisomy 8
- Severe congenital neutropenia (also called *Kostmann syndrome*)
- Inherited genetic polymorphisms
- Having a sibling with a history of ALL

Clincal manifestations

- Symptoms due to:
  - marrow failure
  - tissue infiltration
  - leukostasis
  - constitutional symptoms
  - others- DIC (*acute promyelocytic leukaemia*)
- usually short duration of symptoms

Marrow failure

- Neutropenia: :infections, sepsis
- Anaemia : fatigue, pallor
- Thrombocytopenia: bleeding

Petechiae

Infiltration of tissues/organs

- enlargement of liver, spleen, lymph nodes
- gum hypertrophy
- bone pain
- other organs: CNS, skin, testis, any organ

Figure—Prominent gingival hypertrophy.

AML – gingival hypertrophy

BONE PAIN-ALL

(a)

(b)

T ALL

Constitutional symptoms

- Fever
- Sweats
- Weight loss
- Loss of appetite

Investigations

- FBC+BP
- Bone marrow aspiration & trephine biopsy } demonstrate the presence of excess blasts

- Special stains-Sudan black/PAS } Lineage(Myeloid/lymphoid)
- Flow cytometry
- Cytogenetics

EX: t(15,17) } Help diagnosis/prognosis/MRD assessment
Acute promyelocytic Leukaemia

- Other supportive Ix

Acute Leukemia

- accumulation of blasts in the PB/BM





Photo credit: Mihaela Onciu, MD/St Jude Children's Research Hospital

HOW DO YOU IDENTIFY A BLAST CELL?



- Large nucleus, immature chromatin, a prominent nucleolus, scant cytoplasm and few or no cytoplasmic granules.
- Cell size - Medium to large cells. Larger than a lymphocyte
- Large nucleus -a high N/C ratio
- Immature chromatin - the nuclear chromatin looks as if it composed of fine dots.
- Prominent nucleolus.
- Scant cytoplasm.
- Granules- +/-

  Acute promyelocytic leukemia : Granules+++
- Auer rods - orange-pink, needle-like cytoplasmic structures in blasts of myeloid lineage. These may be numerous in acute promyelocytic leukemia.



AML



Auer rod



Auer rods in Acute promyelocytic leukaemia-Faggot cells



ALL



Distinguishing AML from ALL

- light microscopy
  - AML: Auer rods, cytoplasmic granules
  - ALL: no Auer rods or granules.
- special stains (cytochemistry)
- surface markers (immunophenotype)
- cytogenetics

	Myeloblast	Lymphoblast
		
Size	Larger	Smaller
Cytoplasm	Moderate	Scanty
Auer rod	May be present	Absent
Nuclear chromatin	Fine	Coarse
Nucleoli	Prominent, 1–4	Indistinct

AML

delicate chromatin
much cytoplasm
fine granules/Auer rods



ALL

coarse chromatin
scanty cytoplasm
no granules



Cytochemical Reactions in Acute Leukemia

Cytochemical Reaction	Cellular Element Stained	Blasts Identified
Myeloperoxidase (MPO)	Neutrophil primary granules	Myeloblasts strong positive; monoblasts faint positive
Sudan Black B (SBB)	Phospholipids	Myeloblasts strong positive; monoblasts faint positive
Specific esterase	Cellular enzyme	Myeloblasts strong positive
Nonspecific esterase (NSE)	Cellular enzyme	Monoblasts strong positive
Periodic acid-Schiff	Glycogen and related substances	Variable, coarse or block-like positivity often seen in lymphoblasts and pronormoblasts, myeloblasts usually negative although faint diffuse reaction may occasionally be seen

MYELOBLASTS

Sudan black



- Black staining in cytoplasm



MPO positive

Lymphoblasts- SBB and MPO - Negative

PAS STAIN



LYMPHOBLAST WITH BLOCK & COARSE GRANULAR STAINING

Flow cytometry

Acute Leukemia

AML



B-ALL



T-ALL



t(15;17) translocation in AML

Karyotyping
FISH
PCR







Principles of treatment

Aim: Eradicate the blasts /Establish Normal Bone marrow

- combination chemotherapy
  - first goal is complete remission
  - further Rx to prevent relapse
- supportive medical care
  - transfusions, antibiotics, nutrition
- psychosocial support
  - patient and family

Chemotherapy for ALL

- Phases of ALL treatment
  - Induction
  - intensification
  - CNS prophylaxis
  - Maintenance or transplant

Prognosis for AML

Survival rates greatly improved over past 25 years.

Majority of patients still succumb to the disease.

Remission rates inversely related to age.

- **5-year survival rate in adults under 65 is 33%**
- **5-Year survival rate in adults over 65 is 4%**

Dependent upon several factors.

- **Presence of chromosome translocations in bone marrow**
- **Age**
- **Preceding haematological disorder**

Prognostic factors in AML

parameters	Favorable	unfavorable
Cytogentics	T(15;17). T(8;21). Inv(16).	Deletion of chromosome5or7. 11q23 T(6;9) Abn(3q)complex rearrangments
BM response to remission induction	<5% blasts after first course	>20% blasts after first course.
age	<60yrs	>60yrs

Cure model-based estimates of proportion of infants, children (three age classes), adolescents, and young adults cured of acute lymphoblastic leukemia by diagnosis period (3-year periods from 1982 to 2002) in Europe.



Gemma Gatta et al. Haematologica 2013;98:744-752

haematologica
Journal of the European Hematology Association
Published by the Ferrata Storti Foundation

Prognostic factors in ALL

Table 1 Prognosis Features in Childhood ALL

Risk Factor	Favorable	Unfavorable
Age	1-10 years	<1 or ≥ 10 years
Gender	Female	Male
Race/ethnicity	Caucasian, Asian	Black, Hispanic
White blood cell count at diagnosis	<50,000/µl	≥50,000/µl
Immunophenotype	B-precursor	T-cell, mature B-cell
Genetic features	Hyperdiploidy *ETV6-RUNX1*/t (12;21)	*BCR-ABL1*/t (9;22) *MLL* rearrangement Hypodiploidy iAmp(21) *CRLF2* overexpression
Extramedullary involvement (CNS, testicular)	No	Yes
Early treatment response		
Predisone window	Peripheral absolute blast count <1,0000/µl	Peripheral absolute blast count >1,000/µl
Induction day 8 peripheral blood MRD	<0.01-1%	>1%
Induction day 8 and day 15 bone marrow morphology	M1	M2 or M3
Later treatment response		
End-induction bone marrow MRD	<0.01%	≥0.01%

ALL = acute lymphoblastic leukemia; CNS = central nervous system; MRD = minimal residual disease.

Summary

- Emergency
- Accurate and prompt diagnosis
- Immediate treatment
- ALL is curable
- Out come continue to improve


Thank
You